BACKGROUND: The use of stimulants, such as methamphetamine, has been associated with greater immune activation in treated HIV infection. However, relatively little is known about whether concomitant cannabis use is associated with lower immune activation among HIV-positive stimulant users. SETTING: HIV-positive, sexual minority men with biologically confirmed, recent methamphetamine use were enrolled in San Francisco, CA. METHODS: In total, 78 methamphetamine-using sexual minority men with an undetectable HIV viral load (<40 copies/mL) completed self-report measures of cannabis use and substance use disorder severity. Plasma biomarkers of monocyte activation (ie, sCD14 and sCD163) and intestinal barrier integrity (iFABP) were measured. The associations of hazardous cannabis use with these measurements were examined after adjusting for substance use disorder severity, age, antiretroviral therapy regimen, CD4 T-cell count, and interleukin-6. RESULTS: Hazardous cannabis users had the highest mean sCD14 levels (2181 ng/mL) compared with nonhazardous users (1991 ng/mL) and nonusers (1859 ng/mL; P = 0.05). In adjusted analyses, greater cannabis use severity was associated with higher sCD14 compared with nonusers (unstandardized beta = 133.6 ng/mL, P = 0.03). Cannabis use severity was not significantly associated with sCD163 or iFABP. CONCLUSIONS: Hazardous cannabis use is independently associated with elevations in a clinically relevant marker of immune activation in methamphetamine users with treated HIV.
BACKGROUND: The use of stimulants, such as methamphetamine, has been associated with greater immune activation in treated HIV infection. However, relatively little is known about whether concomitant cannabis use is associated with lower immune activation among HIV-positive stimulant users. SETTING: HIV-positive, sexual minority men with biologically confirmed, recent methamphetamine use were enrolled in San Francisco, CA. METHODS: In total, 78 methamphetamine-using sexual minority men with an undetectable HIV viral load (<40 copies/mL) completed self-report measures of cannabis use and substance use disorder severity. Plasma biomarkers of monocyte activation (ie, sCD14 and sCD163) and intestinal barrier integrity (iFABP) were measured. The associations of hazardous cannabis use with these measurements were examined after adjusting for substance use disorder severity, age, antiretroviral therapy regimen, CD4 T-cell count, and interleukin-6. RESULTS: Hazardous cannabis users had the highest mean sCD14 levels (2181 ng/mL) compared with nonhazardous users (1991 ng/mL) and nonusers (1859 ng/mL; P = 0.05). In adjusted analyses, greater cannabis use severity was associated with higher sCD14 compared with nonusers (unstandardized beta = 133.6 ng/mL, P = 0.03). Cannabis use severity was not significantly associated with sCD163 or iFABP. CONCLUSIONS: Hazardous cannabis use is independently associated with elevations in a clinically relevant marker of immune activation in methamphetamine users with treated HIV.
Authors: Patricia E Molina; Peter Winsauer; Ping Zhang; Edith Walker; Leslie Birke; Angela Amedee; Curtis Vande Stouwe; Dana Troxclair; Robin McGoey; Kurt Varner; Lauri Byerley; Lynn LaMotte Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Patricia E Molina; Angela M Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter J Winsauer; Curtis Vande Stouwe; Robin R McGoey; Matthew W Auten; Lynn LaMotte; Lawrance C Chandra; Leslie L Birke Journal: AIDS Res Hum Retroviruses Date: 2014-02-07 Impact factor: 2.205
Authors: Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek Journal: J Infect Dis Date: 2011-01-20 Impact factor: 5.226
Authors: Joëlla W Adams; Kendall J Bryant; E Jennifer Edelman; David A Fiellin; Julie R Gaither; Adam J Gordon; Kirsha S Gordon; Kevin L Kraemer; Matthew J Mimiaga; Don Operario; Janet P Tate; Jacob J van den Berg; Amy C Justice; Brandon D L Marshall Journal: AIDS Behav Date: 2018-04
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Steven Shoptaw; Jeffrey D Klausner; Cathy J Reback; Stephen Tierney; John Stansell; C Bradley Hare; Steven Gibson; Michael Siever; William D King; Uyen Kao; Jeffrey Dang Journal: BMC Public Health Date: 2006-08-18 Impact factor: 3.295
Authors: Marta Massanella; Sara Gianella; Rachel Schrier; Jennifer M Dan; Josué Pérez-Santiago; Michelli F Oliveira; Douglas D Richman; Susan J Little; Constance A Benson; Eric S Daar; Michael P Dube; Richard H Haubrich; Davey M Smith; Sheldon R Morris Journal: Sci Rep Date: 2015-08-24 Impact factor: 4.379